Sophiris Bio (NASDAQ: SPHS) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Valuation & Earnings
This table compares Sophiris Bio and Theravance Biopharma’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sophiris Bio||N/A||N/A||-$11.16 million||($0.18)||-12.72|
|Theravance Biopharma||$48.65 million||30.00||-$190.66 million||($5.17)||-5.22|
Sophiris Bio has higher earnings, but lower revenue than Theravance Biopharma. Sophiris Bio is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.
This table compares Sophiris Bio and Theravance Biopharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and target prices for Sophiris Bio and Theravance Biopharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sophiris Bio presently has a consensus target price of $6.25, suggesting a potential upside of 172.93%. Theravance Biopharma has a consensus target price of $42.67, suggesting a potential upside of 58.14%. Given Sophiris Bio’s stronger consensus rating and higher possible upside, research analysts plainly believe Sophiris Bio is more favorable than Theravance Biopharma.
Insider and Institutional Ownership
5.5% of Sophiris Bio shares are owned by institutional investors. Comparatively, 86.0% of Theravance Biopharma shares are owned by institutional investors. 3.9% of Sophiris Bio shares are owned by company insiders. Comparatively, 6.1% of Theravance Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Sophiris Bio has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Theravance Biopharma has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.
Sophiris Bio beats Theravance Biopharma on 7 of the 12 factors compared between the two stocks.
Sophiris Bio Company Profile
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.